- Home
- AKRO vs TSLX Comparison
AKRO vs TSLX Comparison
Compare AKRO & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- TSLX
- Stock Information
- Founded
- AKRO 2017
- TSLX 2010
- Country
- AKRO United States
- TSLX United States
- Employees
- AKRO N/A
- TSLX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- AKRO Health Care
- TSLX Finance
- Exchange
- AKRO Nasdaq
- TSLX Nasdaq
- Market Cap
- AKRO 3.9B
- TSLX 2.1B
- IPO Year
- AKRO 2019
- TSLX 2014
- Fundamental
- Price
- AKRO $51.76
- TSLX $24.58
- Analyst Decision
- AKRO Strong Buy
- TSLX Strong Buy
- Analyst Count
- AKRO 6
- TSLX 8
- Target Price
- AKRO $82.50
- TSLX $22.69
- AVG Volume (30 Days)
- AKRO 1.4M
- TSLX 622.0K
- Earning Date
- AKRO 08-08-2025
- TSLX 07-30-2025
- Dividend Yield
- AKRO N/A
- TSLX 8.48%
- EPS Growth
- AKRO N/A
- TSLX N/A
- EPS
- AKRO N/A
- TSLX 1.89
- Revenue
- AKRO N/A
- TSLX $481,092,000.00
- Revenue This Year
- AKRO N/A
- TSLX N/A
- Revenue Next Year
- AKRO N/A
- TSLX N/A
- P/E Ratio
- AKRO N/A
- TSLX $12.98
- Revenue Growth
- AKRO N/A
- TSLX 4.73
- 52 Week Low
- AKRO $21.34
- TSLX $18.58
- 52 Week High
- AKRO $58.40
- TSLX $24.62
- Technical
- Relative Strength Index (RSI)
- AKRO 49.63
- TSLX 68.09
- Support Level
- AKRO $50.04
- TSLX $24.13
- Resistance Level
- AKRO $53.60
- TSLX $24.46
- Average True Range (ATR)
- AKRO 2.20
- TSLX 0.32
- MACD
- AKRO -0.48
- TSLX 0.03
- Stochastic Oscillator
- AKRO 23.53
- TSLX 94.41
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.